Objective The Northern Plains (NP) and Southwest (SW) American Indian populations differ in their smoking patterns and lung cancer incidence. We aimed to compare CYP2A6 genetic variation and CYP2A6 enzyme activity (representative of the rate of nicotine metabolism) between the two tribal populations as these have previously been associated with differences in smoking, quitting, and lung cancer risk.
Introduction
Patterns of commercial tobacco use in the USA differ among ethnic groups, with cigarette smoking being more prevalent in American Indian and Alaska Native (AI/AN) populations compared with other USA populations [1] . However, between different AI/AN tribal populations, prevalence and smoking patterns are also variable, for example between the Northern Plains (NP) and the Southwestern (SW) tribal populations [2, 3] . Despite most AI/ANs wanting to quit smoking and making quit attempts [4] [5] [6] , the prevalence of smoking is 50% in the NP tribal population of South Dakota while only being 14% in the SW tribal population of Arizona [2] and cigarette consumption is higher in the NP relative to the SW (13 vs. 7 cigarettes per day, CPD) [3] . Consistent with this, rates of lung cancer incidence and mortality, to which cigarette smoking has been causally linked, are more than six times higher in the NP compared with the SW tribal population [7, 8] . The underlying reasons for these large differences in tribal smoking and disease risk, whether biological and/or social, are unknown.
One biological influence on smoking is the activity of the hepatic CYP2A6 (cytochrome P450 2A6) enzyme, which varies considerably between individuals and ethnicities [9] . Nicotine, the primary psychoactive component present in cigarette smoke, is metabolically inactivated by CYP2A6 [10] , with the major pathway of inactivation being conversion of nicotine into cotinine (COT) [11] . COT is further metabolized to trans-3′-hydroxycotinine Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (www.pharmacogeneticsandgenomics.com).
(3HC) exclusively by CYP2A6 [12] . Interindividual variation in CYP2A6 enzymatic activity, and thus the rate of nicotine metabolism and clearance, largely results from genetic variation in CYP2A6, the highly polymorphic gene encoding the CYP2A6 enzyme (variants characterized to date found at: http://www.cypalleles.ki.se/cyp2a6. htm). Regular daily smokers alter their levels and intensity of smoking to titrate their nicotine intake such that they maintain desired nicotine levels in the body [13] . Accordingly, CYP2A6 genetic variation and altered rates of nicotine metabolism are associated with differences in smoking behaviors [9] . Smokers with slower rates of nicotine metabolism, those with decrease-of-function and/or loss-of-function CYP2A6 alleles (referred to as reduced metabolizers), often have lower tobacco consumption, dependence, and difficulty quitting smoking compared with faster metabolizers [14] [15] [16] . Among heavy smokers (≥10 CPD), genetically reduced metabolizers smoke fewer CPD compared with smokers with wild-type CYP2A6 genotypes [14] . However, in lighter smoking populations (< 10 CPD), measurement of CPD is not a sensitive measure of tobacco consumption [17, 18] ; whereas light smokers may consume the same number of CPD, they can differ considerably in their smoking topography (puff volume, duration, velocity), and thus overall tobacco consumption [19] . Measurement of urinary total nicotine equivalents (TNEs) is a considerably more precise biomarker of nicotine dose compared with CPD and is the current gold standard for assessing intake [20, 21] . TNE was lower among AN light smokers with decrease-of-function CYP2A6 genotypes, and lower rates of nicotine metabolism, despite no differences in CPD [17] .
In addition to the CYP2A6 genotype, enzyme activity itself is associated with smoking behaviors [22, 23] . CYP2A6 enzymatic activity can be determined in smokers using a ratio of nicotine's metabolites 3HC/COT (nicotine metabolite ratio, NMR), which is highly correlated to the rate of nicotine metabolism and clearance [24] . The NMR is a validated biomarker of CYP2A6 activity because of its stability over time and measurement consistency among heavy and light smokers [25, 26] . Previous studies have confirmed the strong concordance between the CYP2A6 genotype and NMR in multiple populations and ethnic groups, suggesting similar impacts on smoking and lung cancer [18, 27] .
Lung cancer risk is also associated with CYP2A6 genetic variation. Smoking fewer CPD, which has been observed among genetically reduced compared with normal nicotine metabolizers [14] , is associated with a lower risk of lung cancer [28] ; however, the relationship between CYP2A6 and lung cancer risk remains even when controlling for cigarette consumption [29] . One reason for this is that CYP2A6 can also metabolically activate procarcinogenic tobacco-specific nitrosamines; thus, being a slower CYP2A6 metabolizer can reduce both tobacco consumption and procarcinogen activation, resulting in lower lung cancer risk [30] .
Although the impact of individual CYP2A6 alleles/genotypes on the rate of nicotine metabolism has been consistent across ethnicities [18, 27, 31] , patterns of CYP2A6 genetic variation and nicotine metabolism vary considerably between different ethnic groups [27, [32] [33] [34] [35] . To date, no studies have investigated CYP2A6 genetic variation and characterized associations between the CYP2A6 genotype and the rate of enzymatic activity among AI populations, let alone compared two independent tribal groups with contrasting patterns of smoking. Given the distinct patterns of CYP2A6 genetic variation among different ethnic groups, it is plausible that the NP and SW tribal populations show unique patterns of variation at this locus. Therefore, the aim of the current study was to compare CYP2A6 genetic variation and the rate of nicotine metabolism between the NP and SW tribal populations.
Participants and methods

Study design
Members of AI tribal groups were recruited between 2012 and 2014 in South Dakota and Arizona for a study entitled 'Topography and Genetics of Smoking and Nicotine Dependence in American Indians', one of five major research studies carried out by the Collaborative to Improve Native Cancer Outcomes. Recruitment in the NP occurred from a random subset of participants in an earlier study of community health [36] . Recruitment in the SW was conducted using respondent-driven sampling among AI friends and family members of tribal participants in an earlier randomized clinical trial in the greater Phoenix metropolitan area [37] . Both NP and SW subsamples were stratified by sex and smoking status. The final cohort comprised N = 636 AIs aged 20-88 years, with N = 426 in the NP and N = 210 in the SW groups. The urban SW and the predominantly rural NP tribal populations are culturally and linguistically distinct, and have considerably different historical experiences [38] .
Data were collected by trained research staff who were tribal members. Biological samples (blood or saliva) were collected from all participants to be used for genotyping and phenotyping. Personal interviews were conducted and questionnaires were administered to all participants. Ethical approval for all study procedures was obtained from the institutional review boards of the Great Plains Area Indian Health Service, the University of Toronto, the University of Washington, and the MedStar Health Research Institute, and passed through individual tribal approval processes. All participants provided informed consent.
Measures
Data were obtained on age, sex, BMI, smoking status, duration of smoking, CPD, nicotine dependence scores (Fagerström Test for Nicotine Dependence, FTND; Hooked On Nicotine Checklist, HONC), and ceremonial traditional tobacco use. Levels of COT and 3HC were measured in blood or saliva samples using liquid chromatography tandem mass spectrometry as described previously [39] . Our phenotypic measure of CYP2A6 activity, NMR, was defined as the ratio of nicotine's metabolites, 3HC/COT [24] .
Relatedness was determined for all participants on the basis of self-report and genetic analyses. When nuclear families were enrolled, only data on parents (founders) were used to determine allele frequencies; when sibships were enrolled, only one randomly chosen sibling was used. In addition to self-report, relatedness was also assessed by identity-by-descent (IBD) values. These data showed an excellent concordance with the selfreported family data. For individuals who had enrolled as independent, we assessed potential cryptic relatedness and excluded one member of each pair with IBD values of 0.25 or greater. IBD values were computed using SNP and Variation Suite (Golden Helix Inc., Bozeman, MT, USA). Only unrelated participants were included in the comparison of CYP2A6 gene variant frequencies between the two tribal populations. Only self-reported smokers with COT levels above 10 ng/ml have been included in the NMR analyses to ensure smokers had sufficient COT levels that 3HC was quantifiable and formation dependent [39, 40] . NMR is used as a biomarker of CYP2A6 activity in current regular smokers only as steady-state levels of COT and 3HC, achieved through regular cigarette smoking, are necessary for accurate measurement of CYP2A6 activity; this is not a feasible measurement of CYP2A6 activity in nonsmokers in this study [41] .
CYP2A6 genotyping assays DNA was extracted from saliva or blood, and DNA from N = 634 participants (NP, N = 426; SW, N = 208) was genotyped successfully for the following CYP2A6 alleles: *1B, *2, *4, *7, *9, *12, *17, and *35. Genotyping was performed using a two-step allele-specific PCR approach or an allele-specific TaqMan single nucleotide polymorphism genotyping assay (Applied Biosystems) and real-time PCR as described previously [42] . The CYP2A6 alleles *2, *4, *7, *9, *12, *17, and *35 have been associated with a decrease or a loss of CYP2A6 enzyme activity and rates of nicotine metabolism [18, 43, 44] , whereas the *1B allele is associated with faster nicotine metabolism [45] . We have grouped participants as 'normal' or 'reduced' CYP2A6 metabolizers on the basis of the predicted impact of their CYP2A6 genotype. Normal metabolizers had no CYP2A6 decrease-of-function or lossof-function genetic variants, whereas reduced metabolizers had one or more copies of these alleles.
Statistical analyses
NMR was non-normally distributed; thus, nonparametric statistical tests were used. χ 2 -Tests were used to determine Hardy-Weinberg equilibrium and to compare the frequencies of CYP2A6 genetic variants and the overall proportion of participants who were genetically reduced metabolizers between the NP and SW tribal populations. We used Kruskal-Wallis and Dunn's multiple comparisons tests to analyze the association of the CYP2A6 genotype with NMR. Mann-Whitney tests were used to compare NMR between genetically normal versus reduced metabolizers within each tribal population and to compare the overall NMR between the NP and the SW populations.
Linear regression models were run among smokers with COT above 10 ng/ml to determine the percentage of variation in NMR (the output variable) accounted for. Our first model included the variables CYP2A6 genotype, sex, age, BMI, CPD, ceremonial traditional tobacco use, and tribal population (i.e. NP or SW). We also ran separate regression models for each tribal population, in which model variables included the CYP2A6 genotype and BMI. In each model, the CYP2A6 genotype was coded as 0 for individuals with no known CYP2A6 reduced activity alleles (i.e. *1A/*1A, *1A/*1B, *1B/*1B genotypes), − 1 for those with one decrease-of-function allele (i.e. *1/*9 and *1/*12 genotypes), and − 2 for those with one or more loss-of-function or two decrease-offunction alleles (i.e. *1/*2, *1/*4, and *9/*9 genotypes) as done previously [46] . A linear regression model of NMR was also run in wild-type (CYP2A6*1/*1, i.e. individuals who do not have any known CYP2A6 reduced activity genetic variants) smokers only to assess the impact of the increase-of-function CYP2A6*1B genotype and tribal population. In addition, a linear regression model was used to test whether the CYP2A6*1B genotype interacts with tribal populations to influence NMR. The single predictors (CYP2A6*1B genotype and tribal population) were entered into block 1 and the interaction term (CYP2A6*1B genotype × tribal population) was entered into block 2. In both models, the CYP2A6 genotype was coded as 0 for individuals with the *1A/*1A genotype, 1 for those with the *1A/*1B genotype, and 2 for those with the *1B/*1B genotype [45] . Analyses were carried out using GraphPad Prism (version 6.0; La Jolla, CA, USA) and SPSS (version 22; Armonk, NY, USA), and statistical tests were considered significant for P value less than 0.05.
Results
Frequencies of CYP2A6 alleles and genetically reduced nicotine metabolizers CYP2A6 genotype frequencies within each tribal population did not deviate significantly from Hardy-Weinberg equilibrium (P > 0.05). The two NP and SW tribal populations showed distinct frequencies of CYP2A6 Tribal variation in nicotine metabolism Tanner et al. 171 variant alleles from one another and compared with other ethnic groups ( Table 1 ). The frequency of the gain-offunction *1B allele was significantly higher in the NP than the SW (NP 69.7% vs. SW 61.6%, P = 0.01), whereas the prevalence of the decrease-of-function *9 allele was significantly lower in the NP compared with the SW (NP 11.9% vs. SW 20.9%, P = 0.0002). Several alleles that have been found in other ethnic groups were not present in the NP and SW tribal populations (NP *7, *17, *35; SW *7, *17). Next, we categorized individuals into 'normal' or 'reduced' CYP2A6 activity groups on the basis of genotype, with reduced metabolizers defined as individuals who have any decrease-of-function or loss-offunction alleles; this included the following genotypes: *1/*2, *1/*4, *1/*9, *9/*9, *1/*12, and *1/*35. A smaller proportion of the participants from the NP tribal population were CYP2A6 genotype-reduced nicotine metabolizers compared with the SW tribal population (NP 27.5% vs. SW 41.8%, P = 0.0006).
Associations of the CYP2A6 genotype with CYP2A6 activity (nicotine metabolite ratio)
We assessed the rate of CYP2A6 activity, determined by the NMR, among smokers to determine whether the functional impact of the change in each variant CYP2A6 allele was consistent with the impact observed in other populations, and in in-vitro expression systems [48] . The CYP2A6*1B allele had previously been associated with an increased rate of overall nicotine clearance and NMR in vivo [45] , and we observed higher NMR among smokers in both the NP (P = 0.02) and the SW (P = 0.002) tribal populations who had the *1B allele relative to the wild-type *1A allele ( Fig. 1 ; three-group comparison across *1A/*1A, *1A/*1B, and *1B/*1B genotypes). As many decrease-of-function and loss-of-function alleles exist on a variety of *1A or *1B backbones, we have grouped these as the *1/*1 wild-type group for comparisons with the CYP2A6 genotype-reduced activity group (a compilation of all CYP2A6 decrease-of-function and loss-of-function alleles).
The CYP2A6 genotype was associated with CYP2A6 activity such that smokers with one or more decrease-offunction or loss-of-function alleles showed lower mean NMR compared with the *1/*1 reference group (NP, P < 0.0001; SW, P = 0.04; Fig. 2 ). We also observed the presence of a gene-dose effect with the prevalent decrease-of-function *9 allele in both the NP and the SW tribal populations. In the NP tribal population, relative to the wild-type group (*1/*1 genotype), those with one copy of the *9 allele (*1/*9 genotype) had 63.4% CYP2A6 activity and those with two copies of the *9 The P values that were significant (< 0.05) were bolded to highlight statistical significance. Comparison of CYP2A6 activity (NMR) between the wild-type CYP2A6 genotype groups *1A/*1A, *1A/*1B, and *1B/*1B. Individuals included in this analysis do not have any other tested variants. P values for multiple group comparisons (across all three genotypes) are based on Kruskal-Wallis tests. P values comparing between groups are based on Dunn's multiple comparisons tests. One outlier, 1.5 SDs from the mean, was excluded from the plot for illustration purposes, but was included in the statistical analyses (was one of four members of the Northern Plains *1A*1A group, NMR = 1.37). CI, confidence interval; NMR, nicotine metabolite ratio.
(*9/*9 genotype) had 29.6% CYP2A6 activity (Fig. 2) . Similarly, in the SW tribal population, smokers with one and two copies of *9 showed 84.0 and 52.7% CYP2A6 activity, respectively (Fig. 2) .
Comparison of the rate of nicotine metabolism across populations
We compared the rate of nicotine metabolism (i.e. CYP2A6 activity), determined by NMR, between NP and SW smokers, and with additional populations of different ethnic backgrounds. Among all smokers (wild-type and CYP2A6 genotype-reduced metabolizers combined), NP smokers had a faster mean rate of nicotine metabolism relative to SW smokers (P = 0.03; Fig. 3a , Supplementary  Fig. 1a , Supplemental digital content 1, http://links.lww. com/FPC/B186). NP smokers also had a higher mean rate of nicotine metabolism compared with smokers from other ethnic groups, including AN, White, and African American smokers, whose NMR had been assessed previously [18, 27, 49] . When analyses were restricted only to wild-type smokers (those who do not have any known CYP2A6 decrease-of-function or loss-of-function alleles) to avoid the confound of higher or lower frequencies of CYP2A6 genotype-reduced nicotine metabolizers between populations, the rate of nicotine metabolism remained higher among NP smokers compared with SW smokers (P = 0.003) and compared with smokers from other ethnic groups (Fig. 3b, Supplementary Fig. 1b , Supplemental digital content 1, http://links.lww.com/FPC/ B186). In addition, the rate of nicotine metabolism was again higher among NP relative to SW smokers when analyses were restricted to the *1B/*1B group (P = 0.02; Fig. 1 ).
Variables that influence the rate of nicotine metabolism
Using linear regression modeling, we investigated the proportion of variation in the rate of nicotine metabolism (NMR) that was attributable to different predictor variables among smokers in each tribal population, while controlling for the influence of other variables. Both tribal populations were included in a model of NMR in which the CYP2A6 genotype, sex, age, ceremonial traditional tobacco use, BMI, CPD, and tribal population (i.e. NP and SW) were assessed as predictor variables of NMR. Only the CYP2A6 genotype (P < 0.001), BMI (P = 0.03), and tribal population (P = 0.06) each independently accounted for more than 1% of the variation in NMR (Table 2a) . In a second model, we assessed predictors of NMR separately in the NP and SW tribal populations, including only the variables CYP2A6 genotype and BMI (Table 2b and c). These models indicated that, of the variables studied in both tribal populations, the CYP2A6 genotype was the only significant independent predictor of NMR among smokers, accounting for 19.71% (P < 0.001) and 8.12% (P = 0.05) of the variation in NMR in the NP and SW tribal populations, respectively ( Table 2 ).
As we have observed that NP smokers have a higher overall NMR compared with SW smokers, we aimed to determine whether this observation was independent of the effect of the increase-of-function CYP2A6*1B allele, which was expressed at a higher frequency in Fig. 2 Association between the CYP2A6 genotype and CYP2A6 activity (NMR) among smokers. The *1/*1 group represents the normal metabolizers (those who do not have any known CYP2A6 decrease-of-function or loss-of-function alleles; for simplicity, the wild-type *1A and *1B alleles were assessed generically as *1 for these analyses). The reduced metabolizer group (RM) combines all individuals who have one or more decrease-offunction or loss-of-function alleles (i.e. the following genotypes: *1/*2, *1/*4, *1/*9, *9/*9, and *1/*12). P values for multiple group comparisons (across all genotypes) are based on Kruskal-Wallis tests. P values comparing *1/*1 and RM groups are based on Mann-Whitney tests. NMR, nicotine metabolite ratio.
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the NP compared with the SW tribal population. We ran a linear regression model for NMR among wildtype smokers only in which the CYP2A6*1B genotype and tribal population were included as predictor variables. Both variables independently accounted for 6% or more of the variation in NMR (CYP2A6*1B genotype, 7.34%, P = 0.0006; tribal population, 6.00%, P = 0.01; Table 3a ). In addition, using linear regression analyses, we assessed whether there was a significant interaction between the CYP2A6*1B genotype and tribal population in influencing NMR. The interaction term (genotype × tribal population) was not significant (P = 0.72, model R 2 change = 0.001; Table 3b ), suggesting that the relationship between the CYP2A6*1B [18] . CI, confidence interval; NMR, nicotine metabolite ratio. CYP2A6 genotype was coded as 0 for individuals with no known CYP2A6 reduced activity alleles (i.e. *1A/*1A, *1A/*1B, *1B/*1B genotypes), − 1 for those with one decrease-of-function allele (i.e. *1/*9 and *1/*12 genotypes), and − 2 for those with one or more loss-of-function or two decrease-of-function alleles (i.e. *1/*2, *1/*4, and *9/*9 genotypes). c Both tribal populations combined: R 2 = 0.222, P < 0.001. R 2 indicates the proportion of variance in NMR levels (22.2%) that is explained by this model. d NP smokers: R 2 = 0.231, P < 0.001. R 2 indicates the proportion of variance in NMR levels (23.1%) that is explained by this model. e SW smokers: R 2 = 0.092, P = 0.11. R 2 indicates the proportion of variance in NMR levels (9.2%) that is explained by this model. The P values that were significant (< 0.05) were bolded to highlight statistical significance.
genotype and NMR is similar in both tribal populations.
Associations between smoking behaviors and CYP2A6 genotype and activity
Relationships between the CYP2A6 genotype and NMR and smoking behaviors were assessed. There was no difference in the proportion of current and former smokers who were CYP2A6 genotype-reduced metabolizers in either the NP or the SW tribal populations (NP current smokers 31.7%, former smokers 26.7%, P = 0.37; SW current smokers 44.9%, former smokers 41.5%, P = 0.71). There was no association between the following smoking behaviors and CYP2A6 genotype or NMR among either NP or SW self-reported smokers: mean number of CPD, FTND score, HONC score, and duration of smoking (Supplementary Table 1a , Supplemental digital content 2, http://links.lww.com/FPC/B187). Parallel analyses were carried out in which smokers were defined by the more stringent cutoff point of COT above 10 ng/ml; these analyses yielded similar results (Supplementary Table 1b , Supplemental digital content 3, http://links.lww.com/FPC/ B188).
Discussion
We have shown that the NP and SW tribal populations are genetically distinct at the CYP2A6 locus, with the NP population including a lower frequency of CYP2A6 genotype-reduced metabolizers relative to the SW tribal population, while also showing distinct individual allele frequencies. In both cohorts, the CYP2A6 genotype was associated with our phenotypic measure of CYP2A6 activity and rate of nicotine metabolism, NMR. Notably, NP smokers showed a faster overall rate of nicotine metabolism compared with smokers in the SW tribal population and other ethnic groups, even among the CYP2A6 wild-type subgroup. The CYP2A6 genotype and NMR were not significantly associated with smoking behaviors in either tribal population.
The variety of CYP2A6 alleles that were investigated in this study (*1B, *2, *4, *7, *9, *12, *17, *35) was representative of those with a functional impact and those that were prevalent among different ethnic groups [18, 27, 44] . For example, as shown in Table 1 , common CYP2A6 alleles (frequency > 1%) among different ethnic populations include the following: Whites *1B, *2, *4, *9, *12; African Americans *1B, *2, *4, *9, *17, *35; Asians *1B, *4, *7, *9; and ANs *1B, *4, *9 [47] . Choosing to investigate this variety of alleles allowed us to compare CYP2A6 genetic variation between the two populations and characterize the tribal populations with respect to other ethnic groups. We had expected that the pattern of CYP2A6 allele frequencies among both the NP and SW tribal populations would most resemble that of Asian populations as it is postulated that the NP and SW tribal populations have common Asian ancestral origins [50] . However, the CYP2A6*7 allele, which is observed almost exclusively in those of Asian descent, was not present in either tribal population, and both the NP and SW have much lower frequencies of the CYP2A6*4 allele that is common in Asians (see Table 1 ). In addition, we observed significantly different CYP2A6 allele frequencies between the NP and SW tribal populations, suggesting that, if these two populations share common ancestry, there have been incidences of genetic divergence between these two populations. There are several potential explanations for their unique genetic patterns. As each tribal population may have been established by a relatively small sample of original ancestors, a founder effect could have contributed toward the genetic divergence between tribal populations as well as from their ancestors [51] . In addition, because the tribal populations have been geographically separated, factors such as lack of gene flow, random genetic drift, and selective pressures could contribute toward the development of these unique allele frequency patterns [52, 53] .
Not only do the NP and SW tribal populations show different patterns of CYP2A6 allele frequencies, but more specifically, the NP population includes fewer CYP2A6 Table 3 Linear regression analyses of nicotine metabolite ratio among wild-type (*1A/*1A, *1A/*1B, *1B/*1B genotypes) Northern Plains and Southwestern smokers combined into one sample The P values that were significant (< 0.05) were bolded to highlight statistical significance.
genotype-reduced nicotine metabolizers. Considering the strong association that we observed between the CYP2A6 genotype and activity, this suggests that NP smokers will have a faster rate of nicotine metabolism. As stated previously, faster metabolism has been associated with heavier smoking and a higher risk of lung cancer [14] [15] [16] 29] , consistent with the characteristics of the NP compared with the SW tribal population [3, 7, 8] . Phenotypic measurements of CYP2A6 activity also confirmed that the NP tribal population has an elevated rate of nicotine metabolism relative to the SW tribal population and compared with AN, White, and African American populations. This observation was made in the overall population of smokers, but also when excluding smokers with known CYP2A6 decrease-offunction or loss-of-function alleles. The latter finding suggests that the observed elevated rate of nicotine metabolism among NP smokers was not a result of a lower frequency of reduced metabolizers, but rather other factors are contributing toward this, as discussed below. Faster nicotine metabolism may contribute toward an elevated risk for smoking, and tobacco-related disease in the NP relative to the SW as well as in comparison with other ethnic populations in the USA.
To investigate potential contributors to NMR, we performed linear regression modeling in the tribal populations. The CYP2A6 genotype and BMI were the only significant independent contributors to NMR in the combined population sample. However, in this model, tribal population itself trended toward significance, which suggests that there may be unaccounted for differences between the regional tribal populations that explain the observed higher NMR among the NP compared with the SW tribal population. When we investigated each tribal population separately, we found that the CYP2A6 genotype was the only significant independent contributor to NMR in both the NP and the SW tribal populations. Therefore, we investigated whether a possible explanation for the high NMR in the NP tribal population could be their relatively high frequency of the CYP2A6*1B allele (69.7%) compared with the *1B allele frequency in the SW tribal population (61.6%) and other ethnic groups (ANs 65%, Whites 32%, African Americans ∼14%) [27, 54] . CYP2A6*1B was associated with higher NMR in both tribal populations, and in previous studies, with the mechanism believed to be through improving CYP2A6 mRNA stabilization, leading to increased CYP2A6 enzyme expression and activity [45, 55] . However, as NP smokers with the *1B/*1B genotype had significantly higher NMR compared with SW smokers with the same genotype, this suggests that the tribal differences in NMR are not resulting from the higher frequency of *1B in the NP compared with the SW tribal population. As further evidence of this, our linear regression model run only in wild-type smokers indicated that the CYP2A6*1B genotype and tribal population were significant independent predictors of NMR. This suggests that, independent of the CYP2A6*1B genotype, the NP tribal population shows higher NMR than the SW tribal population. We also confirmed that there was no interaction between the CYP2A6*1B genotype and tribal populations in influencing NMR, suggesting that the relationship between the CYP2A6*1B genotype and NMR is similar in both tribal populations and therefore other factors, unrelated to CYP2A6*1B, are contributing toward tribal differences in NMR.
Considering the highly polymorphic nature of the CYP2A6 gene (http://www.cypalleles.ki.se/cyp2a6.htm), there may be novel CYP2A6 genetic variants present in the NP tribal population that act to increase CYP2A6 gene and protein expression and/or enzyme activity. For example, in the NP population, there may be undetected genetic variation present at the 5' promoter region of the CYP2A6 gene that interrupts the binding site for an inhibitory transcription factor, such as C/EBPβ, or creates a binding site for an activating transcription factor, such as HNF4α, thus decreasing or increasing CYP2A6 levels [56] . This may result in greater CYP2A6 promoter activity and thus gene transcription. Variation in regions 3′ of the CYP2A6 gene, similar to the *1B allele, may contribute toward increased mRNA stability and thus increased protein expression [55] , contributing toward higher NMR among NP relative to SW smokers. The significantly higher frequency of CYP2A6*9 in the SW compared with NP supports the concept of ethnicity, or tribal group, specific genetic variation and variant distribution. Assessment of both common and rare variation at the CYP2A6 locus, and in upstream and downstream sequence, by whole CYP2A6 gene sequencing would improve our understanding of the inter-tribe differences in CYP2A6 and nicotine metabolism. In addition, environmental factors can also modulate CYP2A6 activity and the rate of nicotine metabolism. For example, CYP2A6 is inducible by dietary and pharmacological agents such as broccoli, rifampin, and phenobarbital [57] [58] [59] , and therefore potentially by other dietary components of the NP tribal population.
Implications of having a faster rate of nicotine metabolism, as found in the NP tribal population, include greater tobacco consumption, nicotine dependence scores, difficulty quitting smoking, and lung cancer risk [14] [15] [16] 29] . Greater activation of tobacco-specific procarcinogens, such as nitrosamines, because of faster CYP2A6 activity, may explain the higher lung cancer incidence and mortality rates in the NP compared with the SW [7, 8, 30] ; however, our study did not specifically assess this.
When investigating smoking behaviors, we observed that NP smokers consume more CPD (7 vs. 4) have higher nicotine dependence scores (FTND 2.0 vs. 1.8, HONC 4.5 vs. 3.7), and have longer durations of smoking (23 vs. 20 years) (unpublished data from current study; authors JAT, JAH, DB, BVH, PNH, RFT) compared with SW smokers. However, we did not observe an association between the CYP2A6 genotype and NMR with smoking behaviors in either tribal population. This highlights some limitations of our study. First, this lack of association may have resulted from limited statistical power to detect smoking behavior differences between the CYP2A6 genotype and NMR groups because of low sample sizes, particularly of the smokers. The sample size calculations were based on a separate candidate-gene study, carried out as part of the broader 'Topography and Genetics of Smoking and Nicotine Dependence in American Indians' study. In addition, we were limited by available biomarkers and measures of tobacco consumption. The use of a more sensitive biomarker of tobacco consumption, such as TNE, may allow us to detect subtle differences in smoking among these two light smoking populations in the future. Moreover, titration of nicotine intake by CPD according to the rate of nicotine metabolism may not be observed in these AI/AN populations, similar to African American smokers [18, 60] , but titration may be detected with TNE as a measure of consumption, as found among AN smokers [17] .
Conclusion
We have identified distinct patterns of CYP2A6 genetic variation and rates of nicotine metabolism between two AI/AN tribal populations with different smoking patterns and risk for lung cancer. Given the association between faster nicotine metabolism and greater smoking and lung cancer risk, these findings suggest that CYP2A6 may contribute toward an elevated risk for smoking, and tobacco-related disease in the NP compared with the SW and compared with other ethnic populations in the USA. Future work should focus on determining the cause(s) of the faster nicotine metabolism in the NP and assess any causal relationships between their increased rate of metabolism and lung cancer risk and differences in smoking behaviors including cessation, which may in turn inform strategies to mitigate the elevated risk [16, 22] .
